Previous Close | 30.53 |
Open | 30.53 |
Bid | 30.70 x 1100 |
Ask | 33.85 x 800 |
Day's Range | 30.53 - 31.97 |
52 Week Range | 20.24 - 39.43 |
Volume | |
Avg. Volume | 661,952 |
Market Cap | 4.274B |
Beta (5Y Monthly) | 1.36 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.34 |
Earnings Date | Feb 27, 2023 - Mar 03, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 63.21 |
Subscribe to Yahoo Finance Plus to view Fair Value for DNLI
Partner Sanofi has commenced dosing in a Phase 2 clinical trial of SAR443820 (DNL788) in individuals with multiple sclerosisDenali to receive a milestone payment of $25 million from Sanofi for Phase 2 clinical trial initiationDevelopment of RIPK1 inhibitor program continues in a broad range of central nervous system and peripheral inflammatory conditions SOUTH SAN FRANCISCO, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing
Four programs expected to progress in late-stage clinical studies for MPS II (Hunter syndrome), ALS, and Parkinson’s diseaseFurther validation and expansion of Transport Vehicle (TV) technology, including multiple interim clinical data readouts, submission of IND for additional ETV program, and selection of five Oligonucleotide TV (OTV) targetsContinued invention and scientific insights in neurodegeneration biology fuel broad early-stage pipeline of therapeutic candidates SOUTH SAN FRANCISCO, Ca
Every investor in Denali Therapeutics Inc. ( NASDAQ:DNLI ) should be aware of the most powerful shareholder groups. We...